Spyros Papapetropoulos - 18 Nov 2022 Form 4 Insider Report for Vigil Neuroscience, Inc. (VIGL)

Role
Chief Medical Officer
Signature
/s/ Christopher Verni, Attorney-in-Fact
Issuer symbol
VIGL
Transactions as of
18 Nov 2022
Net transactions value
-$3,633
Form type
4
Filing time
22 Nov 2022, 20:45:28 UTC
Previous filing
10 Jun 2022
Next filing
28 Nov 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIGL Common Stock Options Exercise $567 +300 +7.5% $1.89 4,300 18 Nov 2022 Direct
transaction VIGL Common Stock Sale $4,200 -300 -7% $14.00 4,000 18 Nov 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VIGL Stock Option Grant (Right to Buy) Options Exercise $0 -300 -0.2% $0.000000 149,604 18 Nov 2022 Common Stock 300 $1.89 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2022.
F2 25% of the shares subject to this option vested and became exercisable on September 14, 2021, with the remainder vesting in 36 equal monthly installments thereafter.

Remarks:

Exhibit 24 - Power of Attorney